Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bup Woo Kim

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
ANZ Journal of Surgery|July 2, 2014
Tuberculosis cervical lymphadenopathy mimics lateral neck metastasis from papillary thyroid carcinomaSeok-Mo Kim, Hak Hoon Jun, Ho-Jin Chang, et al.
Head & Neck|February 21, 2019
Cost for treatment and follow-up of thyroid cancer increases according to the severity of diseaseSoo Young Kim, Seok-Mo Kim, Hojin Chang, et al.
BMC Cancer|December 25, 2015
Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancerSeok-Mo Kim, Ki-Cheong Park, Jeong-Yong Jeon, et al.
Frontiers in Endocrinology|September 28, 2020
Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective AnalysisSoo Young Kim, Seok-Mo Kim, Jun Won Kim, et al.
Neoplasia (New York, N.Y.)|February 1, 2017
Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid CancerKi Cheong Park, Seok-Mo Kim, Jeong Yong Jeon, et al.
Surgery|May 22, 2018
Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in KoreaKyong Yeun Jung, Seok-Mo Kim, Min Joo Kim, et al.
Clinical Endocrinology|July 16, 2015
Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 yearsKyong Yeun Jung, Seok-Mo Kim, Won Sang Yoo, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
ANZ Journal of Surgery|July 2, 2014
Tuberculosis cervical lymphadenopathy mimics lateral neck metastasis from papillary thyroid carcinomaSeok-Mo Kim, Hak Hoon Jun, Ho-Jin Chang, et al.
Head & Neck|February 21, 2019
Cost for treatment and follow-up of thyroid cancer increases according to the severity of diseaseSoo Young Kim, Seok-Mo Kim, Hojin Chang, et al.
BMC Cancer|December 25, 2015
Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancerSeok-Mo Kim, Ki-Cheong Park, Jeong-Yong Jeon, et al.
Frontiers in Endocrinology|September 28, 2020
Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective AnalysisSoo Young Kim, Seok-Mo Kim, Jun Won Kim, et al.
Neoplasia (New York, N.Y.)|February 1, 2017
Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid CancerKi Cheong Park, Seok-Mo Kim, Jeong Yong Jeon, et al.
Surgery|May 22, 2018
Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in KoreaKyong Yeun Jung, Seok-Mo Kim, Min Joo Kim, et al.
Clinical Endocrinology|July 16, 2015
Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 yearsKyong Yeun Jung, Seok-Mo Kim, Won Sang Yoo, et al.
Pageof 4